Harrow Inc. Reports Q3 2026 Revenue Growth Driven by Branded Products
Harrow, Inc. (HROW) reported strong third-quarter revenue of $99.3 million, representing a 39% increase year-over-year and a 41% sequential rise. This growth was primarily fueled by the company's branded product portfolio, which accounted for 84% of total revenue. Key drivers included VEVYE, which saw 75% year-over-year revenue growth, and TRIESENCE, which achieved its highest quarterly revenue since relaunch. Despite the top-line strength, the company revised its full-year adjusted EBITDA guidance downward to more than $40 million from a previous range of $80 million to $100 million. This revision stems from first-half revenue shortfalls and increased clinical spending. Additionally, the company reported that its QUELL study for IHEEZO failed to meet its primary non-inferiority endpoint regarding ocular surface anesthesia.
Tickers: $HROW
Topics: branded products gross margin R&D expenses revenue growth